RECURSION PHARMACEUTICALS-A (RXRX) Stock Fundamental Analysis

NASDAQ:RXRX • US75629V1044

3.42 USD
-0.3 (-8.06%)
At close: Feb 20, 2026
3.43 USD
+0.01 (+0.29%)
After Hours: 2/20/2026, 8:03:59 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RXRX. RXRX was compared to 521 industry peers in the Biotechnology industry. Both the profitability and financial health of RXRX have multiple concerns. While showing a medium growth rate, RXRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • RXRX had negative earnings in the past year.
  • RXRX had a negative operating cash flow in the past year.
  • RXRX had negative earnings in each of the past 5 years.
  • RXRX had a negative operating cash flow in each of the past 5 years.
RXRX Yearly Net Income VS EBIT VS OCF VS FCFRXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

  • RXRX has a Return On Assets of -51.13%. This is comparable to the rest of the industry: RXRX outperforms 49.14% of its industry peers.
  • The Return On Equity of RXRX (-68.35%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -51.13%
ROE -68.35%
ROIC N/A
ROA(3y)-38.78%
ROA(5y)-35.21%
ROE(3y)-54.96%
ROE(5y)-47.04%
ROIC(3y)N/A
ROIC(5y)N/A
RXRX Yearly ROA, ROE, ROICRXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RXRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RXRX Yearly Profit, Operating, Gross MarginsRXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • RXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RXRX has been increased compared to 1 year ago.
  • The number of shares outstanding for RXRX has been increased compared to 5 years ago.
  • The debt/assets ratio for RXRX is higher compared to a year ago.
RXRX Yearly Shares OutstandingRXRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
RXRX Yearly Total Debt VS Total AssetsRXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • RXRX has an Altman-Z score of -0.14. This is a bad value and indicates that RXRX is not financially healthy and even has some risk of bankruptcy.
  • RXRX has a better Altman-Z score (-0.14) than 60.08% of its industry peers.
  • RXRX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • RXRX has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -0.14
ROIC/WACCN/A
WACC8.68%
RXRX Yearly LT Debt VS Equity VS FCFRXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • RXRX has a Current Ratio of 4.60. This indicates that RXRX is financially healthy and has no problem in meeting its short term obligations.
  • RXRX has a Current ratio of 4.60. This is comparable to the rest of the industry: RXRX outperforms 52.98% of its industry peers.
  • RXRX has a Quick Ratio of 4.60. This indicates that RXRX is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 4.60, RXRX perfoms like the industry average, outperforming 55.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 4.6
RXRX Yearly Current Assets VS Current LiabilitesRXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • RXRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.13%.
  • Looking at the last year, RXRX shows a very negative growth in Revenue. The Revenue has decreased by -32.98% in the last year.
  • The Revenue has been growing by 90.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-16.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.88%
Revenue 1Y (TTM)-32.98%
Revenue growth 3Y79.46%
Revenue growth 5Y90.91%
Sales Q2Q%-80.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.30% on average over the next years.
  • RXRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.46% yearly.
EPS Next Y1.61%
EPS Next 2Y14.11%
EPS Next 3Y11.73%
EPS Next 5Y7.3%
Revenue Next Year-12.97%
Revenue Next 2Y8.12%
Revenue Next 3Y30.16%
Revenue Next 5Y28.46%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RXRX Yearly Revenue VS EstimatesRXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RXRX Yearly EPS VS EstimatesRXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • RXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXRX Price Earnings VS Forward Price EarningsRXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXRX Per share dataRXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.11%
EPS Next 3Y11.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for RXRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RECURSION PHARMACEUTICALS-A

NASDAQ:RXRX (2/20/2026, 8:03:59 PM)

After market: 3.43 +0.01 (+0.29%)

3.42

-0.3 (-8.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-25
Inst Owners60.7%
Inst Owner Change-0.05%
Ins Owners2.09%
Ins Owner Change6.62%
Market Cap1.78B
Revenue(TTM)43.69M
Net Income(TTM)-715.54M
Analysts74.29
Price Target7.14 (108.77%)
Short Float %33.51%
Short Ratio7.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.12%
Min EPS beat(2)-14.85%
Max EPS beat(2)4.61%
EPS beat(4)2
Avg EPS beat(4)-5.99%
Min EPS beat(4)-20.37%
Max EPS beat(4)6.63%
EPS beat(8)6
Avg EPS beat(8)0.03%
EPS beat(12)8
Avg EPS beat(12)-0.78%
EPS beat(16)10
Avg EPS beat(16)-27.82%
Revenue beat(2)1
Avg Revenue beat(2)-24.01%
Min Revenue beat(2)-70.13%
Max Revenue beat(2)22.11%
Revenue beat(4)1
Avg Revenue beat(4)-36.25%
Min Revenue beat(4)-76.78%
Max Revenue beat(4)22.11%
Revenue beat(8)3
Avg Revenue beat(8)-24.17%
Revenue beat(12)3
Avg Revenue beat(12)-23.68%
Revenue beat(16)5
Avg Revenue beat(16)-19.55%
PT rev (1m)0%
PT rev (3m)10.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.6%
EPS NY rev (1m)0%
EPS NY rev (3m)0.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.69
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 3.16
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.08
BVpS2.01
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.13%
ROE -68.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.78%
ROA(5y)-35.21%
ROE(3y)-54.96%
ROE(5y)-47.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.45%
Cap/Sales 14.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.6
Quick Ratio 4.6
Altman-Z -0.14
F-Score4
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)133.89%
Cap/Depr(5y)201.24%
Cap/Sales(3y)47.71%
Cap/Sales(5y)136.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.88%
EPS Next Y1.61%
EPS Next 2Y14.11%
EPS Next 3Y11.73%
EPS Next 5Y7.3%
Revenue 1Y (TTM)-32.98%
Revenue growth 3Y79.46%
Revenue growth 5Y90.91%
Sales Q2Q%-80.16%
Revenue Next Year-12.97%
Revenue Next 2Y8.12%
Revenue Next 3Y30.16%
Revenue Next 5Y28.46%
EBIT growth 1Y-84.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.12%
EBIT Next 3Y-5.16%
EBIT Next 5YN/A
FCF growth 1Y-62.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.7%
OCF growth 3YN/A
OCF growth 5YN/A

RECURSION PHARMACEUTICALS-A / RXRX FAQ

What is the ChartMill fundamental rating of RECURSION PHARMACEUTICALS-A (RXRX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RXRX.


What is the valuation status for RXRX stock?

ChartMill assigns a valuation rating of 0 / 10 to RECURSION PHARMACEUTICALS-A (RXRX). This can be considered as Overvalued.


Can you provide the profitability details for RECURSION PHARMACEUTICALS-A?

RECURSION PHARMACEUTICALS-A (RXRX) has a profitability rating of 1 / 10.


How financially healthy is RECURSION PHARMACEUTICALS-A?

The financial health rating of RECURSION PHARMACEUTICALS-A (RXRX) is 3 / 10.